Your session is about to expire
← Back to Search
Phosphodiesterase Type 5 Inhibitor
Tadalafil for Duchenne Muscular Dystrophy
Phase < 1
Waitlist Available
Led By Ronald Victor, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 times over about 6 weeks
Awards & highlights
Summary
This study, supported by Parent Project Muscular Dystrophy, will determine if tadalafil or sildenafil can improve muscle blood flow during exercise in boys with Duchenne muscular dystrophy.
Eligible Conditions
- Duchenne Muscular Dystrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 times over about 6-weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 times over about 6-weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Functional muscle ischemia
Secondary outcome measures
6 Minute Walk Test
Cardiac Function
EKG Monitoring
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: TadalafilExperimental Treatment1 Intervention
Group II: SildenafilExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tadalafil
FDA approved
Sildenafil
FDA approved
Find a Location
Who is running the clinical trial?
Cedars-Sinai Medical CenterLead Sponsor
503 Previous Clinical Trials
165,843 Total Patients Enrolled
Parent Project Muscular DystrophyOTHER
5 Previous Clinical Trials
10,996 Total Patients Enrolled
Ronald Victor, MDPrincipal InvestigatorCedars-Sinai Medical Center
6 Previous Clinical Trials
106 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger